Skip to content
Screener

Kura Oncology KURA Q2 2025 earnings

Reported August 7, 2025 · After market close

Revenue$15.3MMiss by $49.7M
EPS-$0.75Miss by $0.90
Revenue estimate$64.9M
EPS estimate$0.15

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$23.8M
EPS estimate-$0.84

Financials

Q2 2025

Income statement

See full
Revenue$15.3M+13.5%
Operating income-$72.7M-28.8%
Net income-$66.1M-30.1%
EPS (diluted)-$0.75-27.1%

Balance sheet

See full
Cash & equivalents$81.9M+81.4%
Total debt$19.5M+16.4%
Total equity$305.5M-34.5%
Total assets$682.4M+32.5%

Cash flow

See full
Operating cash flow-$28.8M+32.3%
CapEx$1.5M+9,013%
Free cash flow-$30.2M+28.9%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$517.72M-70.0%
Enterprise value$455.24M-73.2%
P/S9.2×-54.9×

Profitability

See full
Operating margin-390%-122pp
Net margin-350%-114pp
FCF margin218.1%+126pp

Returns & leverage

See full
Return on equity-51.1%+22.1pp
Debt / equity0.1×0.0×
Current ratio6.2×-8.8×

Segments

By product

See full
License And Collaboration Revenue$15.3M+13.5%

FAQ

When did Kura Oncology report Q2 2025 earnings?
Kura Oncology (KURA) reported Q2 2025 earnings on August 7, 2025 after market close.
What were Kura Oncology's Q2 2025 revenue and EPS?
Kura Oncology reported revenue of $15.3M and eps of $-0.75 for Q2 2025.
Did Kura Oncology beat estimates in Q2 2025?
Revenue missed the consensus estimate of $64.9M by $49.7M. EPS missed the consensus estimate of $0.15 by $0.90.
How did Kura Oncology's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 27.1% from $-0.59.
Where can I find Kura Oncology's Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-105024) and the 10-Q periodic report (0000950170-25-105051) directly on SEC EDGAR. The filing index links above go to sec.gov.